LP
VRTX icon

LMR Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

LMR Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.6M Buy
21,500
+16,500
+330% +$7.69M 0.02% 446
2025
Q4 		$2.27M Hold
5,000
– – ﹤0.01% 779
2025
Q3 		$1.96M Buy
+5,000
New +$2.09M 0.01% 739
2025
Q1 		– Sell
-145,200
Closed -$58.5M – 1653
2024
Q4 		$58.5M Buy
+145,200
New +$67.3M 0.49% 28
2024
Q1 		– Sell
-57,800
Closed -$23.5M – 1326
2023
Q4 		$23.5M Buy
+57,800
New +$21.4M 0.27% 89

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LMR Partners's VRTX Position: Q1 2026 in Review

LMR Partners increased its Vertex Pharmaceuticals (VRTX) stake by 21% in Q1 2026, buying an estimated $1.58M and bringing the position to 19,853 shares worth $8.87M. The position accounts for 0.02% of the portfolio, ranked #468.

LMR Partners first reported a position in VRTX in Q4 2014 and has held it in 31 quarters since. The position peaked at $37.8M in Q4 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • LMR Partners held 19,853 shares of Vertex Pharmaceuticals worth $8.87M as of Q1 2026.
  • LMR Partners bought 3,385 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.58M.
  • Vertex Pharmaceuticals made up 0.02% of LMR Partners's portfolio in Q1 2026, its #468 holding.
  • LMR Partners first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 31 quarters since.
  • LMR Partners's Vertex Pharmaceuticals position peaked at $37.8M in Q4 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.